Predictors of chronic hepatitis C evolution in HIV co-infected patients from Romania

Hepatitis Monthly

Volumn 13, Issue 2, 2013, Pages

  Sultana, Camelia ^a,b   Erscoiu, Simona Manuela ^a,c   Grancea, Camelia ^b   Ceausu, Emanoil ^a,c   Ruta, Simona ^a,b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b STEFAN S NICOLAU INSTITUTE OF VIROLOGY   (Romania)

^c VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

Author keywords

Biological markers; Coinfection; Romania

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MNITORING; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROMANIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 84875697927     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.8611     Document Type: Article

References (31)

1. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS.2007;21(9):1073-89.
2. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med.2004;351(5):451-9.
3. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA.2004;292(23):2839-48.
4. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep.2011;8(1):12-22.
5. Compartment for Monitoring and Evaluation of HIV/AIDS infection in Romania. 2012; [cited 30 June]; Available from: http://www.cnlas.ro/images/doc/romania_30iunie2012.pdf.
6. Ruta SM, Matusa RF, Sultana C, Manolescu L, Kozinetz CA, Kline MW, et al. High prevalence of hepatitis B virus markers in Romanian adolescents with human immunodeficiency virus infection. MedGenMed.2005;7(1):68.
7. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill.2011;16(48).
8. Compartment for Monitoring and Evaluation of HIV/AIDS infection in Romania. 2011; Available from: http://www.cnlas.ro/datestatistice.
9. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
10. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med.2002;137(1):1-10.
11. Medrano J, Neukam K, Rallon N, Rivero A, Resino S, Naggie S, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis.2010;51(10):1209-16.
12. Bruno R, Sacchi P, Cima S, Maiocchi L, Patruno SF, Klersy C, et al. Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection. Dig Liver Dis.2011;43(7):575-8.
13. Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, et al. Non-Invasive Prediction of Hepatic Fibrosis in Patients With Chronic HCV Based on the Routine Pre-Treatment Workup. Hepat Mon.2012;12(11).
14. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS.2008;22(15):1979-91.
15. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis.2008;197 Suppl 3:S279-93.
16. Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci.2011;56(10):3038-44.
17. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009; p.
18. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med.2004;351(5):438-50.
19. Kottilil S, Yan MY, Reitano KN, Zhang X, Lempicki R, Roby G, et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology.2009;50(1):34-45.
20. Ingiliz P, Valantin MA, Preziosi P, Finzi L, Pais R, Fedchuk L, et al. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis. J Hepatol.2012;56(1):49-54.
21. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis.2009;49(4):612-22.
22. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS.2010;24(12):1857-65.
23. Gheorghe L, Pascu O, Ceausu E, Csiki IE, Iacob S, Caruntu F, et al. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009. J Gastrointestin Liver Dis.2010;19(2):161-7.
24. Sultana C, Erscoiu SM, Ceausu S, Ruta S. HIV/HCV coinfection in Romania - can we afford not to treat? J Gastrointestin Liver Dis.2012;21(4):441-2.
25. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology.2006;44(6):1617-25.
26. Berenguer J, Fernandez-Rodriguez A, Jimenez-Sousa MA, Cosin J, Zarate P, Micheloud D, et al. High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients. Cytokine. 2012;57(1):25-9.
27. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or nonresponse in HIV-HCV coinfection. Antivir Ther.2008;13(8):969-76.
28. Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology.2010;51(5):1523-30.
29. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A.2008;105(19):7034-9.
30. Cardin Romilda, Saccoccio Gioconda, Masutti Flora, Bellentani Stefano, Farinati Fabio, Tiribelli Claudio. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol. 2001;34(4):587-592.
31. Qu J, Zhang Q, Li Y, Liu W, Chen L, Zhu Y, et al. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol.2012;13:15.